Moderate

Pulmonary Langerhans cell histiocytosis

smoking-related cysts · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Pulmonary Langerhans cell histiocytosis is a smoking-related cystic and nodular lung disease of young adults, with characteristic upper/mid-zone nodules evolving to bizarre-shaped cysts. Smoking cessation is central and often leads to stabilisation or regression.

Red flags

  • Recurrent pneumothorax
  • Development of pulmonary hypertension
  • Multisystem involvement (diabetes insipidus, bone lesions)
  • Rapid functional decline

Assessment

Differential diagnosis

  • Lymphangioleiomyomatosis
  • Centrilobular emphysema
  • Sarcoidosis
  • Metastatic disease / miliary nodules
  • Hypersensitivity pneumonitis

Investigations

  • HRCT chest (upper/mid-zone nodules and irregular/bizarre-shaped cysts, sparing costophrenic angles)
  • Lung function (variable; reduced DLCO common)
  • Smoking history (almost universal)
  • BRAF V600E and related testing in selected/multisystem disease
  • Lung biopsy when the diagnosis is uncertain
  • Screen for extrapulmonary involvement (bone, diabetes insipidus)

Management

  • Suspect in a young adult smoker with upper-zone nodular/cystic lung disease
  • Confirm with characteristic HRCT; biopsy only if atypical
  • Assess physiology and screen for pulmonary hypertension
  • Strongly advise and support complete smoking cessation
  • Monitor for radiological and functional stabilisation/regression after cessation
  • Assess for multisystem Langerhans cell histiocytosis and molecular drivers
  • Consider systemic/targeted therapy for progressive or multisystem disease
  • Manage pneumothorax (recurrent) with definitive intervention
  • Treat pulmonary hypertension with specialist input if it develops
  • Refer progressive respiratory failure for transplant assessment

Drugs & doses

No lung-specific drug for isolated disease — smoking cessation is primary
Smoking-cessation pharmacotherapy (NRT, varenicline)
Cladribine or targeted therapy (e.g. BRAF/MEK inhibitors) for progressive/multisystem disease
Pulmonary hypertension-targeted therapy at expert centres if indicated

Disposition

Respiratory / ILD clinic; smoking-cessation support; haematology input for multisystem disease; transplant for advanced disease.

Complications & pitfalls

  • Recurrent pneumothorax
  • Pulmonary hypertension (often out of proportion)
  • Progressive cystic lung destruction and respiratory failure
  • Extrapulmonary disease progression

Exam pearls

  • Nodules that cavitate into bizarre cysts with upper-zone predominance and costophrenic sparing are classic
  • Almost all patients are current or former smokers — cessation can reverse disease
  • Pulmonary hypertension is common and disproportionate to lung function
  • Consider molecular testing (BRAF) in progressive or multisystem disease

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.